中国临床医学2018，Vol.25Issue(2)：290-295,6.DOI:10.12025/j.issn.1008-6358.2018.20170673
基于基因组学的前列腺癌临床精准诊疗研究进展
The research progress of precision medicine for prostate cancer based on genomics
摘要
Abstract
Prostate cancer is the most common type of cancer in men and the second leading cause of cancer death in men in the United States.The recent surge of high-throughput sequencing of cancer genomes has supported an expanding molecular classification of prostate cancer.T ranslation of these basic science studies into clinically valuable biomarkers for diagnosis and prognosis,and biomarkers which would be predictive for therapy is critical to the development of precision medicine in prostate cancer.We review potential applications aimed at improving screening specificity in prostate cancer and differentiating aggressive versus indolent prostate cancers.Furthermore,we review predictive biomarker candidates involving Ets gene rearrangements,PTEN inactivation,and androgen receptor signaling. These biomarkers and other putative biomarkers may signify aberrant oncogene pathway activation and provide a rationale for matching patients with molecularly targeted therapies in clinical trials.Finally,we advocate innovations for clinical trial design to incorporate tumor biopsy and molecular characterization to develop biomarkers and understand mechanisms of resistance.关键词
前列腺癌/精准治疗/靶向治疗/融合基因/生物标志物Key words
prostatcancer/precision medicine/targetetherapies/fusion gene/biomarker分类
医药卫生引用本文复制引用
顾成元,叶定伟..基于基因组学的前列腺癌临床精准诊疗研究进展[J].中国临床医学,2018,25(2):290-295,6.基金项目
国家自然科学基金(81702537).Supported by National Natural Science Foundation of China(81702537). （81702537）
